~~<i id='52AFB4E86D'><strike id='52AFB4E86D'><tt id='52AFB4E86D'><pre id='52AFB4E86D'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-09-30 15:14:44 Page View：62

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Language on climate change, ESG removed from company website of Montana GOP Senate candidate
Next article： Medical records are filled with copy

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Why the advice to take all your antibiotics may be wrong

APStockYou’vehearditmanytimesbeforefromyourdoctor:Ifyou’retakingantibiotics,don’tstoptakingthemuntil

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Pediatricians' group reaffirms support for gender

Aprotestorwearsatransgenderflagatahearingonbanninggender-affirminghealthcarelegislationinMissouri.AP